

## ITM to Present at the 42<sup>nd</sup> Annual J.P. Morgan Healthcare Conference

**Garching / Munich, Germany, December 21, 2023** – [ITM Isotope Technologies Munich SE \(ITM\)](#), a leading radiopharmaceutical biotech company, today announced that CEO, Steffen Schuster and CFO, Dr. Klaus Maleck will participate in the 42<sup>nd</sup> Annual J.P. Morgan Healthcare Conference in San Francisco. Steffen Schuster will present a corporate overview on Tuesday, January 9, 2024, at 9:00 am PST.

- End -

### **ITM Isotope Technologies Munich SE**

ITM, a leading radiopharmaceutical biotech company, is dedicated to providing a new generation of radiomolecular precision therapeutics and diagnostics for hard-to-treat tumors. We aim to meet the needs of cancer patients, clinicians and our partners through excellence in development, production and global supply. With improved patient benefit as the driving principle for all we do, ITM advances a broad precision oncology pipeline, including two phase III studies, combining the company's high-quality radioisotopes with a range of targeting molecules. By leveraging our nearly two decades of pioneering radiopharma expertise, central industry position and established global network, ITM strives to provide patients with more effective targeted treatment to improve clinical outcome and quality of life.

[www.itm-radiopharma.com](http://www.itm-radiopharma.com)

### **ITM Contact**

#### **Corporate Communications**

Svenja Gärtner / Gerrit Siegers

Phone: +49 89 329 8986 1502

Email: [communications@itm-radiopharma.com](mailto:communications@itm-radiopharma.com)

#### **Investor Relations**

Ben Orzelek

Phone: +49 89 329 8986 1009

Email: [investors@itm-radiopharma.com](mailto:investors@itm-radiopharma.com)